Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
In brief
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab * Learn more about the side effects of BT5528 * Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer. * Learn more about BT5528 therapy alone and in combination with nivolumab.
Key facts
- Study ID
- NCT04180371
- Run by
- BicycleTx Limited
- People needed
- 288
- Starts
- 2019-11-07
- Expected to finish
- 2027-07-31
- Last updated by the study team
- 2025-11-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- California Cancer Associates for Research and Excellence, Inc. — Encinitas, California, United States
- University of California - Irvine Medical Center — Orange, California, United States
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado, United States
- Florida Cancer Specialists — Sarasota, Florida, United States
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Stephenson Cancer Center (Oklahoma University) — Oklahoma City, Oklahoma, United States
- Sidney Kimmel Cancer Center at Thomas Jefferson University — Philadelphia, Pennsylvania, United States
- Sarah Cannon and HCA Research Institute — Nashville, Tennessee, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Virginia Cancer Specialists — Fairfax, Virginia, United States
- Institut Jules Bordet — Brussels, Belgium
- Cliniques Universitaires Saint-Luc — Brussels, Belgium
- Antwerp University Hospital (UZA) — Edegem, Belgium
- Universitair Ziekenhuis Gent (UZ) — Ghent, Belgium
- Gachon University Gil Medical Center — Incheon, South Korea
- Severance Hospital, Yonsei University Health System — Seoul, South Korea
- Institut Catala d'Oncologia - L'Hospitalet — Barcelona, Spain
- Hospital Universitario Vall d'Hebron — Barcelona, Spain
- Hospital Fundación Jimenez Diaz — Madrid, Spain
- Hospital Universitario 12 de Octubre — Madrid, Spain
- Centro Integral Oncologico Clara Campal — Madrid, Spain
- Sarah Cannon Research Institute UK — London, United Kingdom, United Kingdom
- The Christie NHS Foundation Trust — Manchester, United Kingdom, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.